PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non‐small‐cell lung cancer
- 28 August 2018
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 144 (5) , 1092-1103
Abstract
Poly (ADP‐ribose) polymerase (PARP) inhibitors have demonstrated great promise in the treatment of patients with deficiencies in homologous recombination (HR) DNA repair, such as those with loss of BRCA1 or BRCA2 function. However, emerging studies suggest that PARP inhibition can also target HR‐competent cancers, such as non‐small‐cell lung cancer (NSCLC), and that the therapeutic effect of PARP inhibition may be improved by combination with chemotherapy agents. In our study, it was found that PARP inhibitors talazoparib (BMN‐673) and olaparib (AZD‐2281) both had synergistic activity with the common first‐line chemotherapeutic gemcitabine in a panel of lung cancer cell lines. Furthermore, the combination demonstrated significant in vivo antitumor activity in an H23 xenograft model of NSCLC compared to either agent as monotherapy. This synergism occurred without loss of HR repair efficiency. Instead, the combination induced synergistic single‐strand DNA breaks, leading to accumulation of toxic double‐strand DNA lesions in vitro and in vivo. Our study elucidates the underlying mechanisms of synergistic activity of PARP inhibitors and gemcitabine, providing a strong motivation to pursue this combination as an improved therapeutic regimen.Keywords
Funding Information
- Characterized Cell Line Core (CA016672)
- National Cancer Institute (NCI) (T32CA186892)
This publication has 49 references indexed in Scilit:
- Hyperthermia Inhibits Recombination Repair of Gemcitabine-Stalled Replication ForksJNCI: Journal of the National Cancer Institute, 2014
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionCancer Discovery, 2012
- The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistanceNature Reviews Cancer, 2012
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNature Medicine, 2011
- Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature, 2005
- Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forksOncogene, 2004
- Chemotherapy for non-small-cell lung cancer. Part 2: Advanced disease.2003
- Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?2002
- S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.2001
- Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage.Carcinogenesis, 1999